Quantcast

Innovus Pharmaceuticals Receives Notification to Market and Sell CarvaNum® for Muscle Recovery in the European Union

CarvaNum® is the Company’s Fifth E.U. Notified Product

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter
medicine and consumer care products to improve men’s and women’s health
and respiratory diseases, today announced that it has received the CPNP
notification number required to commercialize CarvaNum®, its product for
muscle recovery, in all 28 member countries of the European Union. This
represents the fifth Innovus Pharma product to receive CPNP notification
in the European Union so far, the others being Zestra®, Zestra Glide®,
Sensum+®, and Diabasens®. The product will be available as an over the
counter (“OTC”) or behind the counter product and does not require a
prescription.

“We are pleased to announce the receipt of the CPNP in the European
Union for CarvaNum®. CarvaNum®’s market for muscle recovery is fairly
large in the E.U. and we look forward to growing it along with our other
products in that region,” said Innovus Pharma CEO, Dr. Bassam Damaj. “We
will continue to file for approval for other products in the European
Union, as we expect to grow our approved and/or notified product
portfolio there in 2019 to also include Vesele®, UriVarx®, Prostagorx®,
ArthriVarx®, Trexar® and BH Testosterone®.”

Innovus is also working on filing for CarvaNum® as a homeopathic drug
for muscle cramps in the U.S. and Canada.

About CarvaNum®

CarvaNum® is a proprietary topical product designed as a muscle recovery
cream containing the proprietary ingredient carvacrol to increase muscle
strength, L-Arginine and L-Citrulline for blood flow and magnesium
sulfate to prevent muscle cramps.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging over the
counter (“OTC”) consumer goods and specialty pharmaceutical company
engaged in the commercialization, licensing and development of safe and
effective non-prescription medicine and consumer care products to
improve men’s and women’s health and vitality and respiratory diseases.
Innovus Pharma delivers innovative and uniquely presented and packaged
health solutions through its (a) OTC medicines and consumer and health
products, which we market directly, (b) commercial partners to primary
care physicians, urologists, gynecologists and therapists, and (c)
directly to consumers through our on-line channels, retailers and
wholesalers. The Company is dedicated to being a leader in developing
and marketing new OTC and branded Abbreviated New Drug Application
(“ANDA”) products. The Company is actively pursuing opportunities where
existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com;
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.prostagorx.com;
www.zestra.com;
www.zestraglide.com;
www.fluticare.com;
www.allervarx.com;
www.apeaz.com;
www.diabasens.com;
www.supplementhunt.com
and www.carvanum.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, receiving patent protection for any of its products, to successfully
commercialize CarvaNum® in the European Union and to achieve its other
product development, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company’s most recent annual
report on Form 10-K, and other filings made with the SEC. Copies of
these reports are available from the SEC’s website or without charge
from the Company.

Contacts

Innovus Pharma Investor Relations
Randy Berholtz
Tel:
858-249-7865
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.